Kexing Biopharm Co., Ltd. Class A

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A carries a market capitalization of 4.17B, placing it among publicly traded companies globally. Its enterprise value stands at 5.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kexing Biopharm Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A has 201.26M shares outstanding.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 17.64. The price-to-sales ratio is 3.07, and the price-to-book ratio stands at 2.27.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A trades at an EV/EBITDA multiple of 20.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.14 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.02B versus a market cap of 4.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.40, indicating elevated leverage, while an interest coverage ratio of 5.94 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Kexing Biopharm Co., Ltd. Class A posted a return on equity (ROE) of 13.31, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.39 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.83, useful for judging operating efficiency across full business cycles. The company generates approximately 1.31M in revenue per employee across its workforce of 1,022.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.30 indicates how many times Kexing Biopharm Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kexing Biopharm Co., Ltd. Class A recorded 19.54M in income tax expense. That works out to an effective tax rate of 7.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 249.77M, leaving 233.01M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Kexing Biopharm Co., Ltd. Class A's stock has declined approximately 48.16% over the past 52 weeks. The 50-day moving average sits at 21.32, while the 200-day moving average is 25.24.

Over the twelve months ended June 30, 2026, Kexing Biopharm Co., Ltd. Class A generated 1.34B in revenue and converted that into 233.01M in net income, yielding earnings per share of 1.15. EBITDA reached 249.11M, while operating income came in at -52.32M.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A holds 609.87M in cash and equivalents against 1.46B in total debt, resulting in a net debt position of 374.43M. Total book value stands at 1.84B, with working capital of 386.25M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Kexing Biopharm Co., Ltd. Class A posted a gross margin of 57.93, reflecting its pricing power and cost economics. The operating margin of -3.90 and net profit margin of 17.38 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Kexing Biopharm Co., Ltd. Class A paid dividends of 0.54 per share. The dividend payout ratio of 47.25 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Kexing Biopharm Co., Ltd. Class A shareholders.

As of June 30, 2026, Kexing Biopharm Co., Ltd. Class A has an Altman Z-Score of 1.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.